ME01335B - Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura - Google Patents
Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafuraInfo
- Publication number
- ME01335B ME01335B MEP-2012-42A MEP4212A ME01335B ME 01335 B ME01335 B ME 01335B ME P4212 A MEP4212 A ME P4212A ME 01335 B ME01335 B ME 01335B
- Authority
- ME
- Montenegro
- Prior art keywords
- tegafur
- composition
- administered
- mol
- oxonic acid
- Prior art date
Links
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title claims abstract 37
- 229960001674 tegafur Drugs 0.000 title claims abstract 37
- 206010059024 Gastrointestinal toxicity Diseases 0.000 title claims abstract 11
- 231100000414 gastrointestinal toxicity Toxicity 0.000 title claims abstract 11
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 claims abstract 28
- 239000000203 mixture Substances 0.000 claims abstract 28
- 229950000193 oteracil Drugs 0.000 claims abstract 28
- 150000003839 salts Chemical class 0.000 claims abstract 20
- 230000000259 anti-tumor effect Effects 0.000 claims abstract 8
- 210000002784 stomach Anatomy 0.000 claims 12
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical group OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 229940123171 Dihydropyrimidine dehydrogenase inhibitor Drugs 0.000 claims 8
- 235000012054 meals Nutrition 0.000 claims 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 5
- 229960004316 cisplatin Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 229930192392 Mitomycin Natural products 0.000 claims 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940120638 avastin Drugs 0.000 claims 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 3
- 229960004562 carboplatin Drugs 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 229960001904 epirubicin Drugs 0.000 claims 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 3
- 229960005420 etoposide Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- 229960004857 mitomycin Drugs 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 229960005079 pemetrexed Drugs 0.000 claims 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 235000020937 fasting conditions Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56618004P | 2004-04-29 | 2004-04-29 | |
| PCT/JP2005/008450 WO2005105086A1 (en) | 2004-04-29 | 2005-04-27 | Method for reducing gastrointestinal toxicity due to the administration of tegafur |
| EP05738545A EP1750703B1 (en) | 2004-04-29 | 2005-04-27 | Method for reducing gastrointestinal toxicity due to the administration of tegafur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01335B true ME01335B (me) | 2013-12-20 |
Family
ID=35241420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2012-42A ME01335B (me) | 2004-04-29 | 2005-04-27 | Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080166427A1 (enExample) |
| EP (1) | EP1750703B1 (enExample) |
| JP (1) | JP5376758B2 (enExample) |
| AT (1) | ATE540679T1 (enExample) |
| AU (1) | AU2005237364B2 (enExample) |
| CY (2) | CY1112451T1 (enExample) |
| DK (1) | DK1750703T3 (enExample) |
| ES (1) | ES2378072T3 (enExample) |
| HR (1) | HRP20120293T1 (enExample) |
| ME (1) | ME01335B (enExample) |
| PL (1) | PL1750703T3 (enExample) |
| PT (1) | PT1750703E (enExample) |
| RS (1) | RS52217B (enExample) |
| RU (1) | RU2348409C2 (enExample) |
| SI (1) | SI1750703T1 (enExample) |
| WO (1) | WO2005105086A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010131769A1 (en) * | 2009-05-13 | 2010-11-18 | Taiho Pharmaceutical Co., Ltd. | Treatment of diffuse-type gastric cancers using s-1 and cisplatin |
| BR112012000873A2 (pt) * | 2009-07-17 | 2019-11-05 | Myriad Genetics Inc | método de dosar 5-fluorouracil em uma amostra de um paciente tratado com f-fu ou um pró-fármaco deste, método de tratar um paciente com 5-fluorouracil ou um pró-fármaco deste, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste para um teste de 5-fluorouracil, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste, composição, kit, kit de teste, conjunto de seringa de transferência |
| WO2011022174A1 (en) * | 2009-08-21 | 2011-02-24 | Myriad Genetics, Inc. | Method of processing blood samples containing 5-fu |
| EP2422848A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| EP2422815A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours |
| EP2422784A1 (en) | 2010-08-18 | 2012-02-29 | Grindeks, a joint stock company | Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours |
| MX383483B (es) * | 2014-03-06 | 2025-03-14 | Univ Southern California | Utilización de régimen de ayuno a corto plazo en combinación con inhibidores de cinasa para potenciar la eficacia y viabilidad de fármacos quimioterápicos tradicionales e invertir los efectos secundarios de cinasas en células y tejidos normales. |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| EP3122354B1 (en) | 2014-03-28 | 2022-06-15 | Universita' degli Studi di Genova | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake |
| WO2016175324A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
| JP6439761B2 (ja) * | 2016-08-09 | 2018-12-19 | トヨタ自動車株式会社 | ＮＯｘ吸蔵還元触媒の製造方法 |
| CN106619689B (zh) * | 2016-12-30 | 2018-05-01 | 陈晓华 | 一种用于治疗癌症的药物组合物、试剂盒及其应用 |
| KR20230012572A (ko) * | 2020-05-19 | 2023-01-26 | 셀릭스 바이오 프라이빗 리미티드 | 암을 치료하기 위한 약학 제형 및 이의 제조 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635946A (en) * | 1969-07-22 | 1972-01-18 | Solomon Aronovich Giller | N1-(2'-furanidyl)-derivatives of 5-substituted uracils |
| EP0180188B1 (en) * | 1984-10-30 | 1992-04-15 | Otsuka Pharmaceutical Co., Ltd. | A composition for increasing the anti-cancer activity of an anti-cancer compound |
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| WO1990007334A1 (fr) * | 1989-01-05 | 1990-07-12 | Otsuka Pharmaceutical Co., Ltd. | Agent carcinostatique non injecte permettant de supprimer l'inflammation due a 5-fluorouracil, et procede de traitement du cancer |
| JP2614164B2 (ja) * | 1991-05-27 | 1997-05-28 | 大鵬薬品工業株式会社 | 抗腫瘍効果増強のための及び腫瘍治療のための組成物 |
| US6538001B1 (en) * | 1998-10-12 | 2003-03-25 | Nikolai Borisovich Leonidov | Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect |
-
2005
- 2005-04-27 DK DK05738545.2T patent/DK1750703T3/da active
- 2005-04-27 SI SI200531451T patent/SI1750703T1/sl unknown
- 2005-04-27 WO PCT/JP2005/008450 patent/WO2005105086A1/en not_active Ceased
- 2005-04-27 AU AU2005237364A patent/AU2005237364B2/en not_active Ceased
- 2005-04-27 HR HR20120293T patent/HRP20120293T1/hr unknown
- 2005-04-27 ME MEP-2012-42A patent/ME01335B/me unknown
- 2005-04-27 EP EP05738545A patent/EP1750703B1/en not_active Expired - Lifetime
- 2005-04-27 ES ES05738545T patent/ES2378072T3/es not_active Expired - Lifetime
- 2005-04-27 PL PL05738545T patent/PL1750703T3/pl unknown
- 2005-04-27 RU RU2006142101/14A patent/RU2348409C2/ru active
- 2005-04-27 RS RS20120127A patent/RS52217B/sr unknown
- 2005-04-27 US US11/587,643 patent/US20080166427A1/en not_active Abandoned
- 2005-04-27 PT PT05738545T patent/PT1750703E/pt unknown
- 2005-04-27 AT AT05738545T patent/ATE540679T1/de active
- 2005-04-27 JP JP2006539166A patent/JP5376758B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-07 CY CY20121100222T patent/CY1112451T1/el unknown
- 2012-05-31 CY CY2012014C patent/CY2012014I1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005237364B2 (en) | 2010-07-08 |
| RS52217B (sr) | 2012-10-31 |
| ES2378072T3 (es) | 2012-04-04 |
| PT1750703E (pt) | 2012-02-23 |
| EP1750703A1 (en) | 2007-02-14 |
| EP1750703A4 (en) | 2008-02-27 |
| SI1750703T1 (sl) | 2012-02-29 |
| RU2348409C2 (ru) | 2009-03-10 |
| CY2012014I2 (el) | 2016-04-13 |
| HRP20120293T1 (hr) | 2012-04-30 |
| WO2005105086A1 (en) | 2005-11-10 |
| RU2006142101A (ru) | 2008-06-20 |
| JP2007534634A (ja) | 2007-11-29 |
| CY1112451T1 (el) | 2015-12-09 |
| CY2012014I1 (el) | 2016-04-13 |
| JP5376758B2 (ja) | 2013-12-25 |
| ATE540679T1 (de) | 2012-01-15 |
| DK1750703T3 (da) | 2012-05-07 |
| AU2005237364A1 (en) | 2005-11-10 |
| US20080166427A1 (en) | 2008-07-10 |
| PL1750703T3 (pl) | 2012-05-31 |
| EP1750703B1 (en) | 2012-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1972676B (zh) | 用于个体化应答式给药方案的营养药的组合物和系统 | |
| ME01335B (me) | Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura | |
| US8034808B2 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
| ES2284660T3 (es) | Composicion que contiene un antiofolato y un agente que rebaja el acido metilmalonico. | |
| HRP20110578T1 (hr) | Kombinacije za liječenje bolesti koje uključuju proliferaciju stanica | |
| Heinemann | Gemcitabine-based combination treatment of pancreatic cancer | |
| RS52730B (sr) | Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor | |
| US20080206360A1 (en) | Folate based migraine treatment | |
| JP2007534634A5 (enExample) | ||
| CN104023715A (zh) | 激酶抑制剂的副作用降低剂 | |
| CA2644297A1 (en) | Prevention and treatment of cancer and other diseases | |
| US20150018361A1 (en) | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate | |
| MX2011000511A (es) | Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis. | |
| KR20080003895A (ko) | 아밀로이드증 치료용 제제 및 치료 방법 | |
| JP4610481B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| RU2346686C2 (ru) | Комбинации, включающие эпотилоны и антиметаболиты | |
| SK5032003A3 (en) | Antitumor therapy comprising distamycin derivatives | |
| JP6174044B2 (ja) | Ｅｇｆｒ阻害剤と組み合わせたテトラヒドロフォレート | |
| Kawahara et al. | Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas | |
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer | |
| RU2005121909A (ru) | Профилактика и лечение болезни альцгеймера | |
| CN1330308C (zh) | 含有4－吡啶基甲基酞嗪的联合产品及其应用 | |
| US20110118297A1 (en) | Tivozanib and Temsirolimus in Combination | |
| US20040220265A1 (en) | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide | |
| KR20160038895A (ko) | 암 화학 요법시의 부작용 경감제 |